1. Home
  2. ADTX vs GRI Comparison

ADTX vs GRI Comparison

Compare ADTX & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADTX
  • GRI
  • Stock Information
  • Founded
  • ADTX 2017
  • GRI 2018
  • Country
  • ADTX United States
  • GRI United States
  • Employees
  • ADTX N/A
  • GRI N/A
  • Industry
  • ADTX Biotechnology: Pharmaceutical Preparations
  • GRI Biotechnology: Pharmaceutical Preparations
  • Sector
  • ADTX Health Care
  • GRI Health Care
  • Exchange
  • ADTX Nasdaq
  • GRI Nasdaq
  • Market Cap
  • ADTX 5.3M
  • GRI 6.1M
  • IPO Year
  • ADTX 2020
  • GRI N/A
  • Fundamental
  • Price
  • ADTX $0.13
  • GRI $0.72
  • Analyst Decision
  • ADTX
  • GRI Strong Buy
  • Analyst Count
  • ADTX 0
  • GRI 2
  • Target Price
  • ADTX N/A
  • GRI $11.50
  • AVG Volume (30 Days)
  • ADTX 39.3M
  • GRI 182.9K
  • Earning Date
  • ADTX 11-18-2024
  • GRI 11-14-2024
  • Dividend Yield
  • ADTX N/A
  • GRI N/A
  • EPS Growth
  • ADTX N/A
  • GRI N/A
  • EPS
  • ADTX N/A
  • GRI N/A
  • Revenue
  • ADTX $212,107.00
  • GRI N/A
  • Revenue This Year
  • ADTX $95.61
  • GRI N/A
  • Revenue Next Year
  • ADTX $1,584.79
  • GRI N/A
  • P/E Ratio
  • ADTX N/A
  • GRI N/A
  • Revenue Growth
  • ADTX N/A
  • GRI N/A
  • 52 Week Low
  • ADTX $0.12
  • GRI $0.30
  • 52 Week High
  • ADTX $218.00
  • GRI $65.00
  • Technical
  • Relative Strength Index (RSI)
  • ADTX 18.05
  • GRI 44.58
  • Support Level
  • ADTX $0.12
  • GRI $0.68
  • Resistance Level
  • ADTX $0.21
  • GRI $0.77
  • Average True Range (ATR)
  • ADTX 0.03
  • GRI 0.07
  • MACD
  • ADTX 0.03
  • GRI -0.01
  • Stochastic Oscillator
  • ADTX 9.91
  • GRI 16.44

About ADTX Aditxt Inc.

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: